Question from Deputy Ken O'Flynn - PQ 15874-26
Deputy O'Flynn asked about the full health technology assessment of tirzepatide type 2 diabetes mellitus and for weight management. Read the HSE response.
From: Communications and public affairs
Published: February 2026
Updated: March 2026
Documents
Summary
To ask the Minister for Health further to Parliamentary Question No. 315 of 11 February 2025, and noting that the National Centre for Pharmacoeconomics completed a full health technology assessment of tirzepatide for the treatment of adults with insufficiently controlled type 2 diabetes mellitus on 9 February 2026, and for weight management on 3 December 2025, whether she has been notified of the completion of those assessments; the month in 2026 in which the HSE senior leadership team is scheduled to consider each application for pricing and reimbursement; whether any internal target decision date has been set by her Department or the HSE; and if she will make a statement on the matter. -
This is a beta version - your feedback will help us to improve it